PT  - JOURNAL ARTICLE
AU  - Zheng, Xiaoli
AU  - Liu, Yanqing
AU  - Yu, Qinqin
AU  - Wang, Hua
AU  - Tan, Fuqing
AU  - Zhu, Qianying
AU  - Yuan, Lingmin
AU  - Jiang, Huidi
AU  - Zeng, Su
AU  - Yu, Lushan
TI  - Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”
AID  - 10.1126/scitranslmed.aam6298
DP  - 2017 May 24
TA  - Science Translational Medicine
PG  - eaam6298
VI  - 9
IP  - 391
4099  - http://stm.sciencemag.org/content/9/391/eaam6298.short
4100  - http://stm.sciencemag.org/content/9/391/eaam6298.full
AB  - OCT2 plays a key role in synergy between decitabine and oxaliplatin in renal cell carcinoma cell lines.